ALNYLAM PHARMACEUTICALS, INC. Tax Adjustments, Settlements, and Unusual Provisions
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Tax Adjustments, Settlements, and Unusual Provisions of $20.68 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-15.
Discontinued › Notes › Income Taxes
us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions · last filed 2017-02-15
- ALNYLAM PHARMACEUTICALS, INC. tax adjustments, settlements, and unusual provisions for fiscal 2014 was $20.68M.
| Period end | Tax Adjustments, Settlements, and Unusual Provisions 12 month |
|---|---|
| 2014-12-31 | $20.68M 10-K · filed 2017-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |